Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Functional collagen scaffold in acute spinal cord injury
NCT02510365Phase 1Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Apr 2015
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NeuroRegen Scaffold in spinal cord injury (SCI), sponsored by Chinese Academy of Sciences. Primary endpoint: Number of patients with adverse events at 6 months. Status: unknown.
02
Drugs
NeuroRegen Scaffold
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02510365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510365.